Chongqing Sintaho Pharmaceutical Co., Ltd., founded in 2016, is a high-tech and international enterprise focusing on API R&D and manufacturing, located in Chongqing International Biological City and covering an area of 83 acres. Its holding company - Chongqing Taihao Pharmaceutical Co., Ltd., has been inspected successfully by National Medical Products Administration (NMPA), U.S. Food and Drug Administration (FDA), European Directorate for Quality Medicines (EDQM), Pharmaceuticals and Medical Devices Agency (PMDA) and etc.
Sintaho has built high standard production lines for highly active and toxic APIs in accordance with the international and domestic cGMPs, with a professional EHS and cGMP team covering R&D, production, quality management and regulatory registration, which comprehensively upgrades the management system in accordance with the cGMP regulations, ICH guidelines and EHS management standards, based on years of experience. Sintaho has been committed to building a high-end CDMO platform for oncology APIs with industry influence to produce high quality pharmaceuticals to improve human health.